Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity.

Szabó, Zoltán; Hornyák, Lilla; Miskei, Márton; Székvölgyi, Lóránt

Szabó, Zoltán; Hornyák, Lilla; Miskei, Márton; Székvölgyi, Lóránt.

Afiliación

Szabó Z; Department of Emergency Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Hornyák L; MTA-DE Momentum Genome Architecture and Recombination Research Group, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Doctoral School of Molecular Cell and Immune Biology, Debrecen, Hungary.
Miskei M; MTA-DE Momentum Genome Architecture and Recombination Research Group, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Doctoral School of Molecular Cell and Immune Biology, Debrecen, Hungary.
Székvölgyi L; MTA-DE Momentum Genome Architecture and Recombination Research Group, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Doctoral School of Molecular Cell and Immune Biology, Debrecen, Hungary.

Front Pharmacol ; 11: 569955, 2020.

Article en En | MEDLINE | ID: mdl-33643029

Palabras clave

MAPK/ERK pathway; bax; cancer therapy; cardiotoxicity; clinical trial

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Hungria

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google